Welcome to our dedicated page for Oculis Holding news (Ticker: OCS), a resource for investors and traders seeking the latest updates and insights on Oculis Holding stock.
Oculis Holding AG (OCS) generates a steady flow of news related to its late-stage biopharmaceutical pipeline in ophthalmology and neuro-ophthalmology. Company announcements highlight clinical trial milestones, regulatory designations, capital markets activity, and scientific presentations that are relevant for investors and observers tracking developments in optic neuropathies and retinal disease.
Recent news releases describe the advancement of Privosegtor, a peptoid small-molecule neuroprotective candidate, into the PIONEER registrational program for optic neuritis and non-arteritic anterior ischemic optic neuropathy. Oculis has reported positive Phase 2 ACUITY data in acute optic neuritis and disclosed that Privosegtor has received Breakthrough Therapy designation from the U.S. FDA and Orphan Drug designation from the FDA and EMA. Updates often cover trial design, endpoints such as low-contrast visual acuity, and planned global enrollment.
News coverage also follows OCS-01 eye drops in Phase 3 DIAMOND studies for diabetic macular edema, including the use of the company’s OPTIREACH technology to deliver dexamethasone topically to the retina. In addition, Oculis issues releases on Licaminlimab for dry eye disease, participation in major medical meetings such as the J.P. Morgan Healthcare Conference and ophthalmology congresses, and insider transaction notifications related to restricted stock unit vesting and director share purchases.
For readers monitoring OCS, this news feed provides company-sourced updates on clinical progress, regulatory interactions, financing transactions disclosed in Form 6-K filings, and scientific data presentations. It can be a useful reference for following how Oculis advances its investigational therapies for optic neuritis, NAION, diabetic macular edema, and dry eye disease over time.
Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company specializing in ophthalmic and neuro-ophthalmic conditions, announced its participation in the H.C Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025.
Two key presentations are scheduled: CFO Sylvia Cheung will deliver a corporate update available via webcast at 7:00am ET, while R&D President Snehal Shah will participate in a panel discussion on Pivotal-Stage Assets for Retinal Disorders from 11:00am to 12:00pm ET. Both presentations will be accessible for replay through Oculis' website.
Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company specializing in ophthalmic and neuro-ophthalmic conditions, announced its participation in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025.
Two key presentations are scheduled: CFO Sylvia Cheung will deliver a corporate update available via webcast at 7:00 AM ET, while R&D President Snehal Shah will participate in a panel discussion on Pivotal-Stage Assets for Retinal Disorders from 11:00 AM to 12:00 PM ET. Both presentations will be accessible for replay through Oculis' website.
Oculis Holding AG (Nasdaq: OCS) held its 2025 Annual General Meeting on June 4, 2025, where shareholders approved all agenda items. Key approvals included the 2024 Annual Report, which showed a statutory loss of CHF 5.17 million for 2024, and an accumulated balance sheet loss of CHF 46.57 million.
The meeting resulted in the re-election of Anthony Rosenberg as Board Chair and seven other board members. Shareholders approved compensation packages including USD 2.47 million in fixed compensation for executive committee members and a maximum of USD 15.5 million in equity-based compensation. Additionally, shareholders approved a capital band of 27.26 million registered shares and a conditional share capital for employees of up to 12.48 million shares.
Oculis (NASDAQ: OCS) has amended its loan agreement with BlackRock, significantly expanding its borrowing capacity to CHF 75 million, with potential increase to CHF 100 million. The loan comprises three tranches of CHF 25 million each, plus an additional potential CHF 25 million subject to mutual agreement.
The enhanced facility provides financial flexibility beyond current cash reserves as Oculis approaches key milestones, including FDA discussions for Privosegtor in three indications, initiation of Licaminlimab Phase 2/3 trial, and OCS-01 Phase 3 trial results. The company's current cash position extends runway into early 2028.
Oculis (NASDAQ:OCS) announced the vesting and settlement of Restricted Stock Units (RSUs) for its directors, specifically for CEO Riad Sherif. The company has published the required notifications of transactions by persons discharging managerial responsibilities, in compliance with regulatory requirements.
Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company specializing in ophthalmic and neuro-ophthalmic diseases, has announced its participation in several upcoming investor conferences in May 2025.
The company's leadership team, including CEO Riad Sherif, MD and CFO Sylvia Cheung, will present at four major conferences: Bio€quity Europe in Bruges, Bank of America Healthcare Conference in Las Vegas, H.C. Wainwright Annual BioConnect at Nasdaq in New York, and Stifel Virtual Ophthalmology Forum. One-on-one meetings with investors will be available during these events.
Webcast links for the presentations will be accessible on the Events & Presentation page of the Oculis website under the Investors & Media section.